Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer

Condition:   Stage IV Small Cell Lung Cancer Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Radiation: Stereotactic body radiation therapy Sponsor:   University of Chicago Not yet recruiting - verified July 2017 (Source: ClinicalTrials.gov)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2tyCIJj
via IFTTT